|
|
2014 Featured Talks » Nuclear Receptors: Integrating Molecular Endocrinology and Drug Discovery
Richard Heyman, part 1 from MCC Industry Relations on Vimeo.
Richard Heyman, part 2 from MCC Industry Relations on Vimeo.
Richard Heyman, PhD
Chief Executive Officer
Seragon Pharmaceuticals
Richard A. Heyman, PhD, currently serves as CEO of Seragon Pharmaceuticals, a biotech company recently spun-out of Aragon Pharmaceuticals that focuses on the development of Selective Estrogen Receptor Degraders (SERDs) targeting hormone dependent cancers. He was cofounder and CEO of Aragon Pharmaceuticals, which was purchased by Johnson & Johnson in August 2013 for $650 million in cash upfront along with $350 million in contingent development milestones. Previously, he cofounded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases, which was acquired by Exelixis in 2004. Prior to X-Ceptor, he held various roles at Ligand Pharmaceuticals, including Vice President of Research, where he served as project leader leading to the successful identification and development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Directors for BIOCOM, Organovo Inc., The Jenna Druck Center, a non-profit in San Diego, and is a member of the Therapeutic Advisory Board for aTyr Pharma. He was an NIH postdoctoral fellow and staff scientist at the Salk Institute, working with Dr. Ronald Evans. Dr. Heyman received a PhD in pharmacology from the University of Minnesota and a BS in chemistry from the University of Connecticut.
|
